EnGeneIC Limited has been awarded the Breakthrough in Glioblastoma Biotech Award 2026 at the Northwell Foundation Gala in New York City, recognizing their innovative cyto-immunotherapy platform, the EnGeneIC Dream Vector (EDV™). This technology targets brain tumors by bypassing the blood-brain barrier and delivering cancer treatments directly to cells while activating immune responses. Joint-CEOs, Dr. Himanshu Brahmbhatt and Dr. Jennifer MacDiarmid, expressed their gratitude, highlighting the potential of EDV to improve cancer treatment outcomes. The company is focusing on advancing trials for glioblastoma and other challenging cancers. The event also honored Dr. Bruce Stillman with the Nobility in Science Award for his contributions to scientific research.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://macaubusiness.com/engeneic-honored-with-2026-breakthrough-in-glioblastoma-biotech-award-at-northwell-foundation-lenox-hill-neurosurgery-brain-cancer-gala-in-new-york/
